Abstract
INTRODUCTION
Worldwide obesity has more than doubled since 1980. In 2014, more than 1.9 billion adults, 18 years and older, were overweight and 600 million were obese. Obesity is a major risk factor for coronary artery disease and was the leading cause of death in 2012 [1] . As a consequence, the impact of obesity on outcomes after coronary artery bypass graft (CABG) surgery has become the focus of increasing attention [2] . A high body mass index (BMI) has been consistently associated with poor long-term survival [3] . Its detrimental effect has been attributed to the progression of earlier grafts for atherosclerosis [4] , which leads to a greater risk of clinical events [5] .
Arterial grafts compared with saphenous vein (SV) grafts would be expected to provide a survival benefit in obese patients due to their reduced susceptibility to atherosclerosis [6] . Using the right internal thoracic artery as the second arterial conduit is associated with survival benefit in obese patients undergoing CABG [6] ; however, surgeons continue to be reluctant to use it in this high-risk subgroup because of the potential for sternal wound complications [7, 8] . Therefore, the radial artery (RA) is preferred as the second conduit of choice in obese patients [9] . However, obesity is associated with chronic systemic inflammation, endothelial dysfunction, renin-angiotensin and sympathetic nervous systems activation [10] , which can enhance the vasoreactivity of the RA and early atherosclerosis [11] [12] [13] [14] . In the present study, we tested the hypothesis that the survival benefit from the RA over the SV might be reduced in obese patients compared to non-obese patients undergoing first-time CABG.
MATERIALS AND METHODS
The study was conducted in accordance with the principles of the Declaration of Helsinki. The local audit committee approved the study, and the requirement for individual patient †The first two authors contributed equally to this study. consent was waived. We retrospectively analysed prospectively collected data from the National Institute for Cardiovascular Outcomes Research (NICOR) NACSA registry on 1 June 2015 for all isolated first-time CABG procedures performed at the Bristol Heart Institute, Bristol, UK, from 1996 to April 2015. Reproducible cleaning algorithms were applied to the database, which are regularly updated as required. Briefly, duplicate records and non-adult cardiac surgery entries were removed; transcriptional discrepancies were harmonized; and clinical conflicts and extreme values were corrected or removed. The data are returned regularly to the local units for validation.
Further details and definitions of variables are available at http://www.ucl.ac.uk/nicor/audits/adultcardiac/datasets. Among 12 247 isolated first-time CABG operations performed during the study period, we selected participants who met the following criteria: had multivessel coronary disease including left main or left anterior descending coronary disease; required at least two grafts; had CABG performed using the following strategies: left internal thoracic artery (LITA) grafting and RA as a second arterial conduit with or without additional SV grafts (RA group) or LITA grafting with additional SV grafts only (SV group). In the present series, the RA was considered only when the target stenosis was > _75% and it was used as a free conduit proximally connected to the ascending aorta or as a composite y graft to the LITA. The LITA was used in situ to graft the left anterior descending artery. We classified anyone with a BMI of 30 kg/m 2 and higher as obese, in line with the National Heart Lung and Blood Institute classification of obesity.
End points
The primary end point was all-cause early (within 30 days) and late (beyond 30 days) mortality. All-cause mortality is the most robust and unbiased index because no adjudication is required; thus, inaccurate or biased documentation or clinical assessments are avoided [15] . Information about death was obtained from the institutional database and the General Register Office for all patients.
Statistical analysis
For baseline characteristics, variables are summarized as the median with the relative interquartile range (IQR) for continuous variables and proportion for categorical variables. Multiple imputation was used to address missing data (http://www.jstatsoft.org/ v45/i07/). To control for measured potential confounders in the data set, propensity score (PS) matching was used. A PS was generated for each patient from a multivariable logistic regression model based on pretreatment covariates as independent variables with treatment type (RA vs SV) as a binary dependent variable (http://CRAN.Rproject.org/package=nonrandom). Variables used in the propensity match included age, gender, BMI, baseline creatinine > _ 200 mmol/l, diabetes mellitus, chronic obstructive pulmonary disease, left ventricular ejection fraction < _ 49%, previous myocardial infarction, previous percutaneous coronary intervention, previous cerebrovascular accident, hypertension, current smoking, peripheral vascular disease, preoperative atrial fibrillation, non-elective surgery, preoperative use of intra-aortic balloon pump, diseased vessels including the diagonal branch, circumflex artery and right coronary artery and year of operation. Pairs of patients receiving RA and SV were derived using greedy 1:1 matching with a calliper of width of 0.2 standard deviation of the logit of the PS. Time-segmented Cox regression (within 30 days and beyond 30 days from surgery) was used to investigate the influence of the RA on survival. A second-order interaction between the treatment indicator and the BMI (RA vs SV*BMI) in the matched sample was forced in a time-segmented Cox model for early (within 30 days) and late hazard phases (beyond 30 days). BMI linearity was assessed using a likelihood ratio test, including age as either a linear term or with a restricted spline fit. The likelihood ratio test showed that the cubic term for BMI yielded a better fit than the linear model (v 2 = 12; P = 0.002). A Schoenfeld residuals test ruled out violation of the proportional hazard assumption (P = 0.50). The effect of the RA across BMI values on late mortality was obtained using non-parametric bootstrap covariance analysis for regression coefficients (n = 500 repetitions) (rms R package version 4.2-0: http://CRAN.R-project.org/package=rms). For sensitivity analysis, the effect of the RA on late mortality was tested across BMI categories normal weight (BMI, 18.5-24.9 kg/ m 
RESULTS

Study population
The study population comprised 12 244 patients (median age 68 years, IQR 61-74). Of those, 8740 were non-obese (BMI < 30, median BMI 26, IQR 24-28) and 3504 were obese (BMI > _ 30, median BMI 32, IQR 31-35). The RA was used in 1322 (15%) non-obese patients and 685 (20%) obese patients. The number of procedures using the RA or the SV only among non-obese (BMI < 30) and obese (BMI > _ 30) patients during the study period is shown in Fig. 1 . The mean number of grafts was 2.80 ± 0.70 vs 2.87 ± 0.67 in the RA and SV groups, respectively (P < 0.001). In the non-obese group, the RA was used to graft the right coronary artery in 316 (24%) cases and the circumflex artery in 1006 (76%) cases. In the obese group, the RA was used to graft the right coronary artery in 150 (22%) cases and the circumflex artery, in 535 (78%) cases.
The distributions of pretreatment variables in the RA group and in unmatched and PS-matched SV groups are summarized in Table 1 . Before PS matching, the two groups were not comparable except for four of the pretreatment variables. PS matching selected 2007 SV patients with distributions of pretreatment variables similar to those in the RA group including both BMI categories as well as the mean number of grafts (2.80 ± 0.70 vs 2.81 ± 0.70 in the RA and SV groups, respectively; P = 0.65).
Effect of the radial artery on early and late survival
In the RA group, there were 8 (0.4%) early deaths (within 30 days) compared to 160 (1.6%) in the unmatched SV group (HR early phase 0.25; 95% CI 0.12-0.51; P < 0.001) and 18 (0.9%) in the PS-matched SV group (HR early phase 0.44; 95% CI 0.19-1.02; P = 0.06). After a median follow-up time of 7.5 years (IQR 3.6-11.3), the probability of survival at 5, 10 and 15 years in the RA group was 93.8% ± 0.6%, 84.2% ± 0.9% and 69.4% ± 1.9% compared to 87.7% ± 0.3%, 70.9% ± 0.5% and 51.4% ± 0.08% in the unmatched SV group (HR late phase 0.54; 95% CI 0.48-0.60; P < 0.001, Fig. 2 , left) and 90.9% ± 0.7%, 79.5% ± 1.1% and 63.9% ± 1.6% in the PS-matched SV group (HR late phase 0.86; 95% CI 0.74-0.99; P = 0.04, Fig. 2, right) .
Impact of body mass index on mortality
BMI did not modify the effect of the RA on early mortality (interaction P = 0.43) but there was a significant interaction between BMI and the use of the RA over SV on late mortality (interaction P = 0.02). In particular, the survival advantage conferred by the RA gradually declined as the patient's BMI increased; it was no longer statistically significant above a BMI > 29 (Fig. 3) . The use of the RA reduced the risk of late death in participants with BMI < 30 (HR late phase 0.78; 95% CI 0.65-0.94; P = 0.008; Fig. 4, left) but not in those with BMI > _ 30 (HR late phase 1.05; 95% CI 0.80-1.38; P = 0.72; Fig. 4, right) . Finally, we found a significant interaction between diabetes and the effect of the RA in non-obese patients with a larger benefit among people without diabetes 
DISCUSSION
The main finding of the present study is that the use of the RA in preference to the SV as a second conduit was associated with improved long-term survival in non-obese patients undergoing CABG. The RA-related benefit was more pronounced in the absence of diabetes. However, this benefit was no longer present in obese patients regardless of their diabetes status.
In recent years, the obesity epidemic has grown both in the general population [1] and in patients undergoing CABG [2, 3] . Obesity has been associated with poor long-term outcomes, after CABG, explained by the accelerated progression of the atherosclerotic graft [4, 5] . The use of additional arterial conduits other than the standard LITA has been advocated to improve survival after CABG, given the up to 50% failure of SV grafts at 10 years post-surgery [16] . The RA is often preferred over the second internal thoracic artery in obese patients to reduce the rate of potential sternal wound complications [7, 8] . However, it has been reported that obesity promotes RA vasoreactivity and early inflammation, myointimal hyperplasia and atherosclerotic degeneration in other clinical settings [10] [11] [12] [13] [14] . These observations raise concern about the efficacy of the RA as a second arterial graft in this population.
Obese patients have high levels of serum hs-CRP, which is known to trigger myointimal hyperplasia and a higher tendency toward atheroma and calcification of the RA [11] , suggesting the possibility of pre-existing vascular disease in those patients. Moreover, adiponectin, an adipocyte-derived, collagen-like protein is decreased in obesity. It has been suggested that this situation promotes the production of adhesion molecules in endothelial cells, proliferation of smooth muscle cells and endothelial dysfunction [10] , increased neointimal hyperplasia and atherosclerotic changes in the RA of obese adults [17] .
No previous study has investigated the influence of obesity on survival in patients undergoing CABG using the RA as a second conduit in preference to an SV graft. In the present analysis, we demonstrated that the survival advantage noted in non-obese patients by using the RA is no longer observed in obese patients regardless of their diabetic status.
In a previous study, we found that the use of bilateral internal thoracic arteries improves survival in obese patients undergoing CABG when compared to the conventional strategy with a single internal thoracic artery [6] . It can be speculated that, compared to the RA, internal thoracic arteries might be more resistant to atherosclerosis in obese participants, thus achieving a better patency rate because of their capacity to release nitric oxide [18, 19] .
The present study has some limitations. The study was observational on prospectively collected data, so we cannot exclude selection bias. The propensity technique can adjust only for measurable and included variables, and we cannot exclude a selection bias based on non-measurable 'eye-ball' variables (with the RA reserved for healthier patients). We did not measure the changes in the BMI during the follow-up period; hence, no causality of the interrelationship between these parameters could be determined. In addition, obesity was defined only by the BMI in the present study rather than by an actual measure of adiposity, such as waist circumference. However, the BMI is a widely available, simple, and practical measurement of obesity, and numerous studies have used BMI as a surrogate measure of adiposity [20] . The long period of enrolment could theoretically have affected the preference for the RA as a possible conduit. As shown in Fig. 1 , the rate of RA usage did not vary remarkably over the years. We therefore included the era of surgery in the PS model to account for this confounding factor. However, we cannot exclude residual patient selection bias. Finally, no followup data were available to compare the groups with respect to the cause of death (cardiac vs non-cardiac), recurrence of angina, need for repeated revascularization and graft patency. Therefore, we can only speculate that the mechanism beyond differences in survival rate observed among the groups is related to the differences in patency rates of the RA over the SV.
In conclusion, the survival benefit conferred by the use of the RA in preference to the SV among non-obese patients undergoing CABG was no longer present in obese patients regardless of their diabetic status. Further studies are warranted to determine the pathophysiology underlying this observation and to identify which subgroup of obese patients is more likely to benefit from the use of the RA.
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